Aquestive Therapeutics, Inc.
AQST
$5.39
$0.316.10%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | -78.23M | -68.91M | -83.78M | -68.98M | -65.04M |
| Total Depreciation and Amortization | 544.00K | 548.00K | 574.00K | 588.00K | 608.00K |
| Total Amortization of Deferred Charges | 9.55M | 10.53M | 11.00M | 10.95M | 10.87M |
| Total Other Non-Cash Items | 22.00M | 9.21M | 7.60M | 8.66M | 7.50M |
| Change in Net Operating Assets | 768.00K | 4.79M | 12.18M | -1.67M | -3.62M |
| Cash from Operations | -45.37M | -43.84M | -52.43M | -50.45M | -49.68M |
| Capital Expenditure | -584.00K | -479.00K | -562.00K | -492.00K | -337.00K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -584.00K | -479.00K | -562.00K | -492.00K | -337.00K |
| Total Debt Issued | 54.34M | -- | -- | -- | -- |
| Total Debt Repaid | -45.03M | -28.00K | -26.00K | -26.00K | -27.00K |
| Issuance of Common Stock | 87.61M | 86.93M | 103.53M | 103.02M | 21.72M |
| Repurchase of Common Stock | -3.66M | -503.00K | -877.00K | -860.00K | -992.00K |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -9.36M | -6.00K | -11.00K | -16.00K | -16.00K |
| Cash from Financing | 83.90M | 86.39M | 102.62M | 102.11M | 20.69M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 37.95M | 42.08M | 49.62M | 51.17M | -29.33M |